Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Cortisol in the Treatment of Phobias

This study has been completed.
University Hospital, Basel, Switzerland
Information provided by:
University of Zurich Identifier:
First received: March 21, 2007
Last updated: January 11, 2010
Last verified: January 2010
The aim of this prospective, double-blind, placebo-controlled, randomized study is to investigate if glucocorticoid treatment, in combination with exposure therapy, helps to reduce phobic fear in patients with phobia.

Condition Intervention
Drug: Cortisol

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Efficacy of Cortisol in Combination With Behavioral Therapy in the Treatment of Phobias

Resource links provided by NLM:

Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • visual analog scales for fear and acrophobia questionnaires [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: May 2007
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Cortisol
    20 mg for 3 times

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

- Female and male patients with a specific phobia (fear of heights) according to DSM-IV criteria.

Exclusion Criteria:

  • Severe acute or chronic somatic diseases
  • Psychiatric disorder other than specific phobia
  • Topic glucocorticoid therapy (for large skin parts)
  • Inhaled glucocorticoids
  • Psychotropic medication
  • Pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00451750

University of Basel
Basel, Switzerland, 4055
Sponsors and Collaborators
University of Zurich
University Hospital, Basel, Switzerland
Principal Investigator: Dominique JF de Quervain, MD, Prof. University of Zurich
Principal Investigator: Frank Wilhelm, Prof. University of Basel
  More Information

Responsible Party: Dominique de Quervain, Prof. MD, University of Zurich Identifier: NCT00451750     History of Changes
Other Study ID Numbers: 2007DR3069 
Study First Received: March 21, 2007
Last Updated: January 11, 2010
Health Authority: Switzerland: Swissmedic
Switzerland: Ethical committee, Zürich Switzerland

Keywords provided by University of Zurich:

Additional relevant MeSH terms:
Phobic Disorders
Anxiety Disorders
Mental Disorders
Hydrocortisone 17-butyrate 21-propionate
Cortisol succinate
Hydrocortisone acetate
Anti-Inflammatory Agents processed this record on October 20, 2016